Almoxatone
 | |
| Systematic (IUPAC) name | |
|---|---|
| (5R)-3-{4-[(3-chlorobenzyl)oxy]phenyl}-5-[(methylamino)methyl]-1,3-oxazolidin-2-one | |
| Clinical data | |
| |
| Identifiers | |
84145-89-1  | |
| None | |
| PubChem | CID 172287 |
| ChemSpider |
150582  |
| UNII |
85V47MCE4Z |
| ChEMBL |
CHEMBL2104006 |
| Chemical data | |
| Formula | C18H19ClN2O3 |
| 346.81 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Almoxatone (MD-780,236) is a selective and reversible inhibitor of MAO-B.[1][2] It was patented as an antidepressant and antiparkinsonian agent but was never marketed.[3]
See also
References
- ↑ Tipton KF, Fowler CJ, McCrodden JM, Strolin Benedetti M (January 1983). "The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-(4-[(3-chlorophenyl)methoxy]phenyl)-5-[(methylamino) methyl]-2-oxazolidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions". The Biochemical Journal 209 (1): 235–42. PMC 1154077. PMID 6847610.
- ↑ Dostert P, Strolin Benedetti M, Guffroy C (March 1983). "Different stereoselective inhibition of monoamine oxidase-B by the R- and S-enantiomers of MD 780236". The Journal of Pharmacy and Pharmacology 35 (3): 161–5. doi:10.1111/j.2042-7158.1983.tb04297.x. PMID 6132973.
- ↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||